East Coast fever Vaccine Frontier Research Project ILRI, TIGR, Ludwig Cancer Institute (Belgium), University of Edinburgh,...
Frontier Research Project <ul><li>Poor success in developing vaccines to induce cell-mediated immunity   </li></ul><ul><li...
T.parva  vaccine research portfolio Brown ear tick Schizont infected cells Sporozoites Piroplasms Merogony Anti-sporozoite...
Partners and Main Interests <ul><li>DFID-UK </li></ul><ul><li>Leadership in brokering / funding research innovation for de...
Project management <ul><li>Funding and project oversight (DFID)  </li></ul><ul><li>grant to ILRI (UK£ 5 million over 4 yea...
ECF VACCINE RESEARCH STRATEGY - ROLES ANTIGEN IDENTIFICATION ANTIGEN DELIVERY sequencing  Proteomics ACGCTGCATC CTAGCCTAAA...
Milestone management <ul><li>Joint planning and agreement on milestones coordinated by ILRI and agreed by DFID </li></ul><...
Partnerships, Confidentiality and IP <ul><li>Partnership and confidentiality agreements </li></ul><ul><li>Partnership agre...
Project Outputs and Outcomes <ul><li>Sequence of T. parva, 10 candidate antigens that induce cell-mediated immune response...
Next Steps and Issues Arising <ul><li>ECF vaccine portfolio   </li></ul><ul><ul><li>ILRI in partnership with GALVmed and o...
International Livestock Research Institute Better lives through livestock Animal agriculture to reduce poverty, hunger and...
Upcoming SlideShare
Loading in …5
×

East Coast Fever Vaccine Frontier Research Project

1,445 views

Published on

Presentation by John McDermott to the CGIAR Alliance Deputy Executive (ADE) and Private Sector Committee (PSC) Workshop on Public Private Partnerships , November 11-13, 2009, Zurich, Switzerland.

http://www.cgiar.org/psc/

Published in: Technology, Business
0 Comments
2 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
1,445
On SlideShare
0
From Embeds
0
Number of Embeds
20
Actions
Shares
0
Downloads
23
Comments
0
Likes
2
Embeds 0
No embeds

No notes for slide
  • Original proposal UK£ 15 million over 6 years
  • Important research culture change
  • Layered IP – combination of public access and flexibility with exclusivity linked to private IP
  • Important research culture change
  • Important research culture change
  • East Coast Fever Vaccine Frontier Research Project

    1. 1. East Coast fever Vaccine Frontier Research Project ILRI, TIGR, Ludwig Cancer Institute (Belgium), University of Edinburgh, University of Oxford, Merial, UK-DFID Presentation by John McDermott to the CGIAR Alliance Deputy Executive (ADE) and Private Sector Committee (PSC) Workshop on Public Private Partnerships November 11-13, 2009, Zurich, Switzerland http://www.cgiar.org/psc
    2. 2. Frontier Research Project <ul><li>Poor success in developing vaccines to induce cell-mediated immunity </li></ul><ul><li>Research Objectives </li></ul><ul><li>Identify parasite antigens recognized by CD8 cells </li></ul><ul><li>Prepare vaccine constructs and assess immunogenicity </li></ul><ul><li>Test protection against challenge </li></ul>
    3. 3. T.parva vaccine research portfolio Brown ear tick Schizont infected cells Sporozoites Piroplasms Merogony Anti-sporozoite antibodies Anti-schizont cellular response Live vaccine Controlled infection
    4. 4. Partners and Main Interests <ul><li>DFID-UK </li></ul><ul><li>Leadership in brokering / funding research innovation for development </li></ul><ul><li>ILRI </li></ul><ul><li>Previous investment in basic biology </li></ul><ul><li>Exploit new technologies </li></ul><ul><li>Demonstrate research contribution to development </li></ul><ul><li>TIGR </li></ul><ul><li>Genomics approaches can contribute to vaccine research </li></ul><ul><li>Merial </li></ul><ul><li>Interest in future products for tropical animal health portfolio </li></ul><ul><li>Access to science expertise to inform vaccine development </li></ul>
    5. 5. Project management <ul><li>Funding and project oversight (DFID) </li></ul><ul><li>grant to ILRI (UK£ 5 million over 4 years) </li></ul><ul><li>semi-annual project review (management and technical) to agreed project milestones updated semi-annually </li></ul><ul><li>Overall project management (ILRI) </li></ul><ul><li>planning, coordination (weekly teleconferences, semi-annual team meetings), communication, milestone management, subgrants </li></ul><ul><li>Management of components (Partners) </li></ul><ul><li>Internal management with reporting to ILRI manager </li></ul><ul><li>Major in-kind contributions (TIGR/ILRI, Merial) </li></ul>
    6. 6. ECF VACCINE RESEARCH STRATEGY - ROLES ANTIGEN IDENTIFICATION ANTIGEN DELIVERY sequencing Proteomics ACGCTGCATC CTAGCCTAAA ATCGTCCTAT AACGTACGAT TATTTACGAT Random cDNA Oxford technology COS cell transfection 500-1000 Genes Evaluation in Cattle Candidate Genes Rapid Screening Assays – Antigens Identified Cloning PROOF OF CONCEPT (Evaluation in Cattle) ELISPOT 2001 2001 2001 2002/3 2003/4 2002 Merial technology TIGR LCI ILRI ILRI Merial Oxford ILRI
    7. 7. Milestone management <ul><li>Joint planning and agreement on milestones coordinated by ILRI and agreed by DFID </li></ul><ul><li>Overall objectives and milestones maintained but details adapted during regular team meetings (every 6 months) </li></ul><ul><li>Close interaction between oversight and management teams </li></ul><ul><li>Specific stop-go criteria agreed in advance </li></ul>
    8. 8. Partnerships, Confidentiality and IP <ul><li>Partnership and confidentiality agreements </li></ul><ul><li>Partnership agreements and confidentiality agreements </li></ul><ul><li>Early confidentiality agreement between ILRI and Merial (pre-project) to explore interests </li></ul><ul><li>Initial challenges in practice trust and culture between public and private – overcome over the project </li></ul><ul><li>Exclusivity of commercial relationship with Merial during project period </li></ul><ul><li>Intellectual Property </li></ul><ul><li>Public antigen discovery IP captured through patents held by public partners with support from Merial </li></ul><ul><li>Any vaccine product IP resulting would be held by Merial in discussion with public contributors pending research results. </li></ul>
    9. 9. Project Outputs and Outcomes <ul><li>Sequence of T. parva, 10 candidate antigens that induce cell-mediated immune responses </li></ul><ul><li>Better and faster approaches to antigen identification for cell-mediated immunity established (and used by others) </li></ul><ul><li>Enhanced research management culture in ILRI and establishment of joint innovation in the partnership </li></ul><ul><li>“ Proof-of-concept” vaccine constructs </li></ul><ul><ul><li>Correlates of cell-mediated immunity consistently demonstrated </li></ul></ul><ul><ul><li>Protection against lethal challenge when cytolytic cellular responses demonstrated </li></ul></ul><ul><ul><li>Cytolytic responses inconsistently induced (30%) </li></ul></ul><ul><li>No vaccine constructs provided agreed protection (stop to further commercial development) </li></ul>
    10. 10. Next Steps and Issues Arising <ul><li>ECF vaccine portfolio </li></ul><ul><ul><li>ILRI in partnership with GALVmed and others pursuing a market access partnership for live vaccine (ILRI produces the vaccine) </li></ul></ul><ul><ul><li>Sporozoite vaccine pending (Intervet) </li></ul></ul><ul><li>Open innovation approaches / platforms </li></ul><ul><ul><li>Issue of exclusivity (R-D stage, </li></ul></ul><ul><ul><li>“ Interest” among public and private partners in more open collaboration around early stages of vaccine research (EU technology platform) </li></ul></ul><ul><ul><li>ILRI convened meetings of public and private partners to develop a concept note </li></ul></ul>
    11. 11. International Livestock Research Institute Better lives through livestock Animal agriculture to reduce poverty, hunger and environmental degradation in developing countries www.ilri.org

    ×